Omega-3 supplementation may improve HbA1c, lipid profile among T2DM patients

  • O'Mahoney LL & al.
  • Cardiovasc Diabetol
  • 7 Jul 2018

  • from Sarfaroj Khan
  • Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Omega-3 polyunsaturated fatty acids (n-3PUFAs) supplementation was associated with improvement in lipid profile, inflammatory markers, and significant improvement in HbA1c among patients with type 2 diabetes mellitus (T2DM).
  • Treatment duration, dosage did not modify these improvements.

Why this matters

  • Randomised controlled trials (RCTs) suggest that supplementation with n-3PUFAs may favourably modify cardiometabolic biomarkers in T2DM.
  • Previous meta-analyses are limited by insufficient sample sizes and omission of meta-regression techniques

Study design

  • Meta‑analysis and meta‑regression of 45 RCTs including 2674 patients with T2DM from inception until 13 July 2017.
  • Effect of n-3PUFAs supplementation on lipid profiles, inflammatory parameters, BP and indices of glycaemic control was assessed.
  • Funding: Institute for Sport, Physical Activity and Leisure at Leeds Beckett University, and the AGADA Diabetes Education and Research Institute.

Key results

  • n-3PUFAs supplementation use showed significant reductions in low-density lipoprotein (LDL; effect size [ES], −0.10; 95% CI, −0.17 to −0.03; P=.007), very LDL (ES, −0.26; 95% CI, −0.51 to −0.01; P=.044), triglycerides (ES, −0.39; 95% CI, −0.55 to −0.24; P≤.001) and HbA1c (ES, −0.27; 95% CI, −0.48 to −0.06; P=.010).
  • Use of n-3PUFAs supplementation showed a moderate reduction in levels of TNF-α (ES, −0.68; 95% CI, −1.32 to −0.03; P=.039) and IL-6 (ES, −1.67; 95% CI, −3.14 to −0.20; P=.026). 

Limitations

  • Risk for bias.
  • Small number of trials.